Skip to page content Search
Home / Programmes and Contracts / Community Pharmacy Programme / Services delivered under ICPSA

Services delivered under ICPSA

 

Skip to...

Opioid Substitution Treatment Services (including Co-dispensing)

Aseptic Services

Sterile Manufacturing Services

Clozapine Services (Monitored Therapy Medicine Services)

Immunisation Services

Long Term Conditions (LTC) Pharmacy Services

Community Residential Care (CRC) Pharmacy Services

Age-Related Residential Care (ARRC) Pharmacy Services

Special Foods Service

Community Pharmacy Anti-coagulation Management Services (CPAMS)

Smoking Cessation Services

Local Commissioning

As part of an integrated health service, a range of pharmacy services are available to individuals and whānau in communities across Aotearoa beyond regular dispensing of prescribed medicines. Each service is described in more detail in Schedule 3 of the ICPSA contract .

If a publication is described but not linked here, please refer to our 'Publications and Resources' page. If you can't find a document, please contact us at:

Email: pharmacy@tas.health.nz 

Publications and Resources


Opioid Substitution Treatment Services (including Co-Dispensing)

Opioid Substitution Treatment Services provide appropriate access to comprehensive, integrated, and continuing services guided by harm reduction philosophies. Opioid Substitution Treatment Services applies only to services associated with methadone or Suboxone (buprenorphine+naloxone) when prescribed for the treatment of opioid dependence, and does not cover services associated with the use of those medicines for other indications, such as pain.

The services in this program include, for example, dispensing methadone and Suboxone, ensuring dispensing is appropriately packaged, supervising consumption of these medicines, and assisting patients to comply with prescribed medicines.

If a patient receiving Opioid Substitution Treatment Services also receives other prescribed medicines, then the pharmacy may be able to register that patient for  Co-dispensed Opioid Services, and receive a higher payment for dispensing those other medicines.

The eligibility criteria for registering a patient with CDOS are set out in the ICPSA.
For more information about this service, refer to Schedule 3A.1 in the ICPSA.


Aseptic services

This service enables Service Users to have appropriate access to services for which the preparation of an aseptic preparation, including a syringe driver for approved pumps.

For more information about this service, refer to Schedule 3A.2 in the ICPSA.


Sterile manufacturing services

This service is specific to the preparation of eye drops and other products requiring sterile manufacturing, and does not apply in respect of Pharmaceuticals that require aseptic preparation.

For more information about this service, refer to Schedule 3A.3 in the ICPSA. 


Clozapine services (monitored therapy medicine services)

This service is for patients prescribed clozapine. Each time a pharmacy dispenses clozapine, it needs to obtain and monitor full blood count test results, liaise with the pharmaceutical supplier of the relevant brand of clozapine to update and maintain complete individual patient records, and liaise with prescribers as appropriate in the monitoring and interpretation of blood results.

Clozapine Dispensing Information for Community Pharmacists

To ensure the safety of all individuals prescribed clozapine, you should be aware of the Clozapine Protocol published by Te Whatu Ora. This document’s aim is to ensure the safe dispensing of clozapine and that appropriate processes are in place for the monitoring of blood results. 

Clozapine Protocol [333kb]

October 2018

You should also be familiar with the Medsafe datasheets for all funded brands of clozapine. These are available at Medsafe’s page of datasheets.

The best and safest solution is to work with the individual’s Multi-Disciplinary Team (MDT) and/or their residential care facility manager to ensure the dispensing cycle and tests align. See the top tips section (below) to support you.

Dispensing should generally take place within 24-72 hours of the date of the most recent blood test for the relevant individual. This requirement may vary according to the hospital or health service protocol that applies in your locality. You will need to customise procedures for your pharmacy accordingly.

What you need to be doing

  1. Register the individual in your medicines supplier’s monitoring website
  2. Record the date of each clozapine dispensing in your suppliers website 
  3. Adhere to the national or local clozapine Protocols. 

Each of the above actions are outlined in the Clozapine Protocols to ensure that individuals' clozapine dispensing is recorded and can be monitored and viewed by the prescriber and MDT to make sure there is continuity of care. 

Top tips
To maintain the continuity of supply of clozapine for each individual, improve your workflow and promote your clinical value with the MDT use the following tips: 

1. Proactive care - Strengthen the relationship with the MDT by proactively monitoring and care planning for the individual. Proactive care means making sure you become an active member of the MDT that anticipates and plans for problems.

Ways you can provide proactive care:

  • Set up reminder systems for you, your patient and their MDT about the impending need for a blood test or new prescription to ensure smooth delivery of care
  • Check the individual’s blood tests before their next dispensing. You could do this before they present their clozapine prescription. This way you can have an early conversation with their MDT when blood tests are overdue or causing concern.
  • Plan ahead for any possible disruptive issues that individual might encounter and contact their prescriber to prevent this. 
  • Contact the individual's prescriber to discuss and agree contingency plans if blood test history suggests
    • impending neutropenia (because they are trending down or classed as an amber)

    • neutropenia (a red result).

2. Assess their eligibility for registration into the Long Term Conditions Service (LTC).

If you spend a significant amount of time with this individual managing their access and adherence to medication, they may qualify for this service based on medicines adherence issues.  

 For more information about this service, refer to Schedule 3A.4 in the ICPSA.


Immunisation Services

Pharmacies who have the Immunisation Service Schedule in their ICPSA may provide immunisations to eligible service users in accordance with the Immunisation Standards, such as influenza vaccination and the measles, mumps, and rubella vaccination.

For more information about this service, refer to Schedule 3A.5 in the ICPSA.

Long-Term Conditions (LTC) Pharmacy Services

The LTC service is designed to support patients with long-term conditions and identified medicine adherence issues. It aims to improve the patient’s health outcomes by improving adherence, perseverance, and managing any changes to those medicines.

Who is eligible for the LTC Service?

The Eligibility is set in the LTC Services Protocol. There are both entry and exit criteria, and pharmacies have a responsibility to regularly assess each registered patient to check if the exit criteria are met.

Further, there are caps on the number of LTC registrations by geographic area. Contract-holders can contact  their Portfolio Manager for further details.

What does the LTC Service provide for patients?

A patient in the LTC program should have their health outcomes improved. This should come from improving their understanding of all their medicines, assistance in adhering to and persevering with their medicines regime, assistance in managing any prescribed changes to that regime, having their pharmacist work with all other clinicians who provide the patient with care, and ideally lead to one shared care plan.

This may be achieved by advisory services during dispensing, tailoring dispensing frequency, medicines reconciliation services, synchronisation services, reminder services, screening of the patient’s compliance and adherence to their medicines regime, and engagement between the pharmacist and other clinicians.

LTC Service Users visiting a different pharmacy

People registered for the LTC Service may have reasons for visiting another pharmacy. Generally, it is to get medicine for ‘acute instances’ when a person is discharged from hospital or has had a specialist appointment. 

If a patient seeks a dispensing from your pharmacy while registered for LTC with another pharmacy, you don’t have an obligation to provide that patient with the LTC services.

If a patient is registered with your pharmacy for LTC services, but ends up regularly getting dispensing from a different pharmacy, then they meet the exit criteria and you will need to exit them from your service.

LTC Resources for Pharmacists

LTC Service Protocol [324kb]

October 2018

Optional Patient registration form [185kb]

January 2014

LTC service patient leaflet [673kb]

June 2015

Medicines reconciliation [70kb]

July 2015

Medicines synchronisation [34kb]

July 2015

More LTC service patient case studies [409kb]

June 2015

For more information about this service, refer to Schedule 3B.1 in the ICPSA. 


Community Residential Care (CRC) Pharmacy Services

Residents in Community Residential Care facilities are eligible to use this service. A key component of this service is delivery of prescribed medicines to facilities.

For more information about this service, refer to Schedule 3B.2 in the ICPSA.


Age-Related Residential Care (ARRC) Pharmacy Services

Residents in Aged Residential Care facilities are eligible to use the service. A key component of this service is delivery of prescribed medicines to facilities.

A ‘reasonable interpretation’ of the Age Related Residential Care Service Specifications has been created to support you work with GPs and ARRC facilities to provide pharmacy services. It provides guidance to help you understand what services you are and are not funded to provide and what is realistically expected of you. Contact your Portfolio Manager for more information.

Reasonable interpretation of the ARC Service Specifications [482kb]

November 2018


For more information about this service, refer to Schedule 3B.3 in the ICPSA.


Special Foods Services

This service is for Service Users who are Eligible Persons who are prescribed Special Foods.

For more information about this service, refer to Schedule 3B.4 in the ICPSA.


Community Pharmacy Anti-coagulation Management Services (CPAMS)

The Community Pharmacy Anti-coagulation Management Service (CPAMS) provides point of care testing and dose adjustments for warfarin patients. An accredited pharmacist performs this service. 

Who is eligible for the service?

Patients on 'warfarin' referred by their GP.

How is the service delivered?

A GP must refer patients to use the service. Instead of going to the laboratory for each test, an accredited community pharmacist can measure INR levels using just a small sample of blood from a finger prick.

Which community pharmacies are providing CPAMS?

Download the latest list of providers.

CPAMS Providers List [201kb]

September 2022

How CPAMS is being delivered

View the latest national CPAMS Quality Report to see how community pharmacies are delivering the Service. The Report uses INR Online (software provider) data so show quality measures of care such as:

  • Number of bleeds
  • Time in Therapeutic Range (TTR)
  • Timeliness of testing

National Quality Report Jan-Jun 2022 [624kb]

October 2022 

National Quality Report July-Dec 2021 [618kb]

September 2022 

National Quality Report Jan-Jun 2021 [612kb]

September 2022

National Quality Report July-Dec 2020 [263kb]

May 2021

National Quality Report Jan-Jun 2020 [640kb]

May 2021

National Quality Report July-Dec 2019 [334kb]

April 2020

National Quality Report Jan-June 2019 [309kb]

September 2019 

National Quality Report July-Dec 2018 [261kb]

April 2019 

National Quality Report Jan-June 2018 [344kb]

September 2018


Each pharmacy can also get a report specific to them and their work, based on the same quality measures of care. This enables you to compare and assess your pharmacy's service delivery. You can get this report from your Portfolio Manager. 

CPAMS Resources for pharmacists working with patients

CPAMS fact sheet for patients [93kb]

May 2021

CPAMS fact sheet for primary and community care [107kb]

May 2021

Suggestions for getting started [366kb]

March 2017

Patient registration and consent form [276kb]

September 2015

CPAMS case studies [221kb]

September 2015

Letter to patients – template for pharmacists [21kb]

September 2016

Information to help pharmacists get started with CPAMS

Standard Operating Procedure [219kb]

November 2013

GP referral form [776kb]

November 2013

Letter to general practice – template for pharmacists [25kb]

September 2016

CPAMS invoicing and reporting requirements [445kb]

October 2018

Standing orders for CPAMS [491kb]

November 2013

Pre-requisites for providing the Service [31kb]

September 2012

Advice on INR test options for patients away from home [297kb]

March 2017


Smoking Cessation Services

Evidence-based interventions are the focus of the Smoking Cessation Services that includes providing information about access and use of approved cessation pharmacotherapies, and behavioural support, which may be delivered in many ways including telephone, online, and face to face (individually or group based).

For more information about this service, refer to Schedule 3B.6 in the ICPSA.


Local commissioning

There is provision within the contract for new local services to be developed by Te Whatu Ora working collaboratively with local community pharmacies and pharmacists, other health providers, and community groups.

If you wish to get involved in development of new local services, here are some contacts.

District contacts

 

Back to top

Last updated: 13/11/22